Bliss Gvs Pharma Share PriceBliss GVS Pharma

₹91.8
0.4 (0.44%)
As on 22 September, 2023 | 08:20 BSE: 506197 NSE: BLISSGVSISIN: INE416D01022

Bliss Gvs Pharma Performance

Day Range

  • Low 91
  • High 92.95
91.8

52 Week Range

  • Low 69.2
  • High 104
91.8
  • Open Price91.5
  • Previous Close91.4
  • Volume161793

Start SIP in Bliss GVS Pharma

Start SIP

Bliss Gvs Pharma Share Price

  • Over 1 Month -0.43%
  • Over 3 Month 11.41%
  • Over 6 Month 22.07%
  • Over 1 Year 11.81%

Bliss Gvs Pharma Key Statistics

P/E Ratio 16
PEG Ratio 0.1
Market Cap Cr 958
Price to Book Ratio 1
EPS 8.2
Dividend 0.5
Relative Strength Index 43.99
Money Flow Index 28.5
MACD Signal 0.31
Average True Range 3.74

Bliss Gvs Pharma Investment Rating

  • Master Rating:
  • Bliss Gvs Pharma has an operating revenue of Rs. 722.45 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 14% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 5%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 14% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 11% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 15 which is a POOR score indicating inconsistency in earnings, a RS Rating of 55 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 81 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma Financials
IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 109143169139147138
Operating Expenses Qtr Cr 98133135112128129
Operating Profit Qtr Cr 11113327199
Depreciation Qtr Cr 544443
Interest Qtr Cr 151222
Tax Qtr Cr 32111077
Net Profit Qtr Cr 762925259
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 649669
Operating Expenses Annual Cr 508527
Operating Profit Annual in Cr 90109
Depreciation Cr 1514
Interest Annual Cr 104
Tax Annual Cr 3034
Net Profit Annual Cr 8593
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 44114
Cash from Investing Activity Annual Cr -13-92
Cash from Financing Annual Activity Cr -26-13
Net Cash Flow Annual Cr 59
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 937851
Fixed Assets Annual Cr 328247
Total Non Current Assets Annual Cr 410289
Total Current Assets Annual Cr 730791
Total Assets Annual Cr 1,1401,080
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 9082
ROE Annual % 911
ROCE Annual % 1314
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2422
IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 160185206172189167
Operating Expenses Qtr Cr 135179158148150147
Operating Profit Qtr Cr 24648253920
Depreciation Qtr Cr 655554
Interest Qtr Cr 151222
Tax Qtr Cr 7-4184123
Net Profit Qtr Cr 15328142620
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 769779
Operating Expenses Annual Cr 634629
Operating Profit Annual in Cr 117118
Depreciation Cr 1917
Interest Annual Cr 105
Tax Annual Cr 2931
Net Profit Annual Cr 7115
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 34135
Cash from Investing Activity Annual Cr -8-93
Cash from Financing Annual Activity Cr -25-24
Net Cash Flow Annual Cr 219
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 884819
Fixed Assets Annual Cr 374296
Total Non Current Assets Annual Cr 459333
Total Current Assets Annual Cr 697776
Total Assets Annual Cr 1,1571,109
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 8882
ROE Annual % 82
ROCE Annual % 1215
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1820

Bliss Gvs Pharma Technicals

EMA & SMA

Current Price
₹91.8
0.4 (0.44%)
  • Bullish Moving Average
  • ___
  • 5
  • Bearish Moving Average
  • ___
  • 11
  • 20 Day
  • ₹94.31
  • 50 Day
  • ₹92.48
  • 100 Day
  • ₹88.17
  • 200 Day
  • ₹84.13
  • 20 Day
  • ₹95.58
  • 50 Day
  • ₹94.96
  • 100 Day
  • ₹85.93
  • 200 Day
  • ₹80.27

Bliss Gvs Pharma Resistance and Support

PIVOT
₹91.92
Resistance
First Resistance ₹92.84
Second Resistance ₹93.87
Third Resistance ₹94.79
RSI 43.99
MFI 28.5
MACD Single Line 0.31
MACD -0.36
Support
First Resistance ₹90.89
Second Resistance ₹89.97
Third Resistance ₹88.94

Bliss Gvs Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 189,061 8,991,741 47.56
Week 235,443 13,549,716 57.55
1 Month 349,194 16,618,163 47.59
6 Month 334,786 16,679,057 49.82

Bliss Gvs Pharma Result Highlights

Bliss GVS Pharma Synopsis

NSE-Medical-Generic Drugs

Bliss Gvs Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 598.34 Cr. and Equity Capital is Rs. 10.42 Cr. for the Year ended 31/03/2023. Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771.
Market Cap 958
Sales 560
Shares in Float 6.79
No of funds 24
Yield 0.54
Book Value 1.02
U/D Vol ratio 2
LTDebt / Equity 4
Alpha 0.04
Beta 0.56

Bliss GVS Pharma

Owner NameJun-23Mar-23Dec-22Sep-22
Promoters 35.12%35.04%34.46%34.55%
Mutual Funds
Insurance Companies 6.62%6.63%6.63%6.64%
Foreign Portfolio Investors 16.5%16.6%16.53%16.68%
Individual Investors 30.1%30.01%30.73%30.57%
Others 11.66%11.72%11.65%11.56%

Bliss GVS Pharma Management

Name Designation
Mr. S R Vaidya Chairman & Ind.Director
Mr. Gagan Harsh Sharma Managing Director
Dr. Vibha Gagan Sharma Whole Time Director
Mrs. Shruti Vishal Rao Whole Time Director
Mr. Santosh L Parab Independent Director
Mrs. Shilpa Bhatia Independent Woman Director

Bliss Gvs Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Bliss Gvs Pharma Corporate Action

Date Purpose Remarks
2023-08-01 Quarterly Results
2023-05-11 Audited Results & Final Dividend
2023-01-24 Quarterly Results
2022-11-07 Quarterly Results
2022-08-03 Quarterly Results

Bliss GVS Pharma MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 8
  • Company Name
  • CMP
  • Chg(%)
  • Company Name
  • CMP
  • Chg(%)

Bliss GVS Pharma FAQs

What is Share Price of Bliss GVS Pharma ?

Bliss GVS Pharma share price is ₹91 As on 22 September, 2023 | 08:06

What is the Market Cap of Bliss GVS Pharma ?

The Market Cap of Bliss GVS Pharma is ₹958.4 Cr As on 22 September, 2023 | 08:06

What is the P/E ratio of Bliss GVS Pharma ?

The P/E ratio of Bliss GVS Pharma is 16 As on 22 September, 2023 | 08:06

What is the PB ratio of Bliss GVS Pharma ?

The PB ratio of Bliss GVS Pharma is 1 As on 22 September, 2023 | 08:06

Q2FY23